Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Army
Federal Trade Commission
Julphar
QuintilesIMS
Colorcon
Fuji
Citi
Covington

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,444,779

« Back to Dashboard

Summary for Patent: 4,444,779
Title: Thiazolidine derivatives
Abstract:Thiazolidine derivatives of the general formula: ##STR1## [wherein R.sup.1 is alkyl, cycloalkyl, phenylalkyl, phenyl, a five- or six-membered heterocyclic group including one or two hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur or a group of the formula ##STR2## (where R.sup.3 and R.sup.4 are the same or different and each is lower alkyl or R.sup.3 and R.sup.4 are combined to each other either directly or as interrupted by a hetero-atom selected from the group consisting of nitrogen, oxygen and sulfur to form a five- or six-membered ring); R.sup.2 means a bond or a lower alkylene group; L.sup.1 and L.sup.2 are the same or different and each is lower alkyl or L.sup.1 and L.sup.2 are combined to form an alkylene group, provided that when R.sup.1 is other than alkyl, L.sup.1 and L.sup.2 may further be hydrogen, respectively] are novel compounds and useful as, for example, remedies for diabetes, hyperlipemia and so on of mammals including human beings.
Inventor(s): Kawamatsu; Yutaka (Kyoto, JP), Fujita; Takeshi (Takarazuka, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:06/476,017
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 4,444,779
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 4,444,779

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,444,779

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan53-95673Aug 4, 1978

International Family Members for US Patent 4,444,779

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 1131644 ➤ Try a Free Trial
Germany 2963585 ➤ Try a Free Trial
Denmark 325079 ➤ Try a Free Trial
Denmark 149023 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Argus Health
Chubb
US Department of Justice
Farmers Insurance
Teva
Julphar
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.